For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $11.41 in the prior trading day, KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $11.31, down -0.92%. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 0.78 million shares were traded. KALV stock price reached its highest trading level at $11.72 during the session, while it also had its lowest trading level at $11.1.
Ratios:
Our goal is to gain a better understanding of KALV by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.44 and its Current Ratio is at 10.44. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 09 ’25 when Palleiko Benjamin L sold 7,169 shares for $14.50 per share. The transaction valued at 103,950 led to the insider holds 315,074 shares of the business.
Audhya Paul K. sold 2,146 shares of KALV for $24,272 on May 23 ’25. The CHIEF MEDICAL OFFICER now owns 113,026 shares after completing the transaction at $11.31 per share. On May 23 ’25, another insider, Yea Christopher, who serves as the CHIEF DEVELOPMENT OFFICER of the company, sold 1,926 shares for $11.31 each. As a result, the insider received 21,782 and left with 98,189 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 566508288 and an Enterprise Value of 314614272.
Stock Price History:
The Beta on a monthly basis for KALV is -0.03, which has changed by -0.017810583 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $15.50, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is -9.32%, while the 200-Day Moving Average is calculated to be 3.63%.
Shares Statistics:
The stock has traded on average 750.49K shares per day over the past 3-months and 1581940 shares per day over the last 10 days, according to various share statistics. A total of 49.49M shares are outstanding, with a floating share count of 38.49M. Insiders hold about 22.58% of the company’s shares, while institutions hold 88.37% stake in the company. Shares short for KALV as of 1749772800 were 6253523 with a Short Ratio of 8.33, compared to 1747267200 on 6111379. Therefore, it implies a Short% of Shares Outstanding of 6253523 and a Short% of Float of 14.2.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.74 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$3.34 and -$3.82 for the fiscal current year, implying an average EPS of -$3.56. EPS for the following year is -$2.98, with 9.0 analysts recommending between -$2.53 and -$3.75.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $29.88M in the next fiscal year. The high estimate is $46M and the low estimate is $15.76M.
